<SEC-DOCUMENT>0001558370-25-011925.txt : 20250908
<SEC-HEADER>0001558370-25-011925.hdr.sgml : 20250908
<ACCEPTANCE-DATETIME>20250908160516
ACCESSION NUMBER:		0001558370-25-011925
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20250906
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250908
DATE AS OF CHANGE:		20250908

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adaptimmune Therapeutics PLC
		CENTRAL INDEX KEY:			0001621227
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37368
		FILM NUMBER:		251300040

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		60 JUBILEE AVENUE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		PROVINCE COUNTRY:   	X0
		BUSINESS PHONE:		44 1235 430000

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		60 JUBILEE AVENUE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		PROVINCE COUNTRY:   	X0

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adaptimmune Ltd
		DATE OF NAME CHANGE:	20141001
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>adap-20250906x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 11.0.0.3 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 9/8/2025 2:56:53 PM -->
<!-- iXBRL Library version: 1.0.9292.28120 -->
<!-- iXBRL Service Job ID: c453aa60-22af-4b36-8087-81fb21dd04a9 -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:adap="http://www.adaptimmune.com/20250906" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w" name="dei:EntityCentralIndexKey" id="Tc_58pe7063q0m0r0D_9NhQVQ_2_1">0001621227</ix:nonNumeric><ix:nonNumeric contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w" name="dei:AmendmentFlag" id="Tc_LS-i8fAZJUaDNZsmco3xZw_3_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w" name="dei:EntityTaxIdentificationNumber" id="Hidden_sChDiFw5FkehkAukQBvJMw">00-0000000</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="adap-20250906.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001621227</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-09-06</xbrli:startDate><xbrli:endDate>2025-09-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b70502e6_29b7_4cac_9f32_eb23bb68fe28"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES </b><b style="font-size:18pt;font-weight:bold;"><br/></b><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w" name="dei:DocumentType" id="Narr_LbTcta_tYE20g7G0DIGAdg"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Current Report</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Date of Report (Date of earliest event reported):<b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="Narr_MsjkMKVYEkqgVdF5Zmtf6A"><b style="font-weight:bold;">September 6, 2025</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w" name="dei:EntityRegistrantName" id="Narr_auvOSjmgKkyoGXd3yxwugw"><b style="font-weight:bold;">ADAPTIMMUNE THERAPEUTICS PLC</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a955ef0e_e52b_4858_9ce4_6782eccbb535"></a><a id="Tc_8nTp-uJKkEKbmP5Gbt2Oyg_2_0"></a><a id="Tc_fEn9uLJwIU-juHC1D4mt3g_2_2"></a><a id="Tc_bI4g-L4YPkG_BVrnFhhIow_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="Tc_ZfAjvfG7lEWDuP2VdtidOA_1_0"><b style="font-weight:bold;">England and Wales</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w" name="dei:EntityFileNumber" id="Tc_zhue9xRsVkGMKq_iHFxfSQ_1_2"><b style="font-weight:bold;">1-37368</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_sChDiFw5FkehkAukQBvJMw;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Not Applicable</b></span></p></td></tr><tr><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(State or other jurisdiction of<br/>incorporation)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Commission File Number)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(IRS Employer Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w" name="dei:EntityAddressAddressLine1" id="Narr_LePotmiYzkyyn10bXKaisw"><b style="font-weight:bold;">60 Jubilee Avenue</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w" name="dei:EntityAddressAddressLine2" id="Narr_oTPY53SGN0ek5ruIR8wW5g"><b style="font-weight:bold;">Milton Park</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w" name="dei:EntityAddressCityOrTown" id="Narr_kvFhmtvvAkiFRxsFFNKGzA"><b style="font-weight:bold;">Abingdon, Oxfordshire</b></ix:nonNumeric><b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w" name="dei:EntityAddressPostalZipCode" id="Narr_CxUgOQBt1U-ZqQpWWoQU1Q"><b style="font-weight:bold;">OX14 4RX</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="Narr_yMp4hFXDfkSXcyqGt0O5og"><b style="font-weight:bold;">United Kingdom</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Address of principal executive offices, including zip code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w" name="dei:CityAreaCode" id="Narr_hrlMBQLMPkyIe8EnHiNBtA"><b style="font-weight:bold;">44</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w" name="dei:LocalPhoneNumber" id="Narr_FWNo0f6xUEeW3tl_0x3OeQ"><b style="font-weight:bold;">1235 430000</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="display:inline-block;text-indent:0pt;width:23.1pt;"><ix:nonNumeric contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_VzFAY9KztkGCTSeUajjTqw"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span>Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="display:inline-block;text-indent:0pt;width:23.1pt;"><ix:nonNumeric contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_vL6nLoZXsk-D2kM4neUjFw"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span>Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="display:inline-block;text-indent:0pt;width:23.1pt;"><ix:nonNumeric contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_NtIKpyDxC0y8NEpKoksEQw"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span>Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 25.9pt;"><span style="display:inline-block;text-indent:0pt;width:23.1pt;"><ix:nonNumeric contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_MzQRM9AAXEeBQ53S57vjUg"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span>Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_602dac61_edc2_4936_8590_9ecf753fb00c"></a><a id="Tc_iRQmjVLK-U2Viw7ZsprWAA_0_0"></a><a id="Tc_99ruz9sP-Ey4yRJrTfX4Vw_0_2"></a><a id="Tc_sJgymLtYpU6ntw67YEkHfg_0_4"></a><a id="Tc_2kcqAowiXE2_UU67wSWHQg_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title&#160;of&#160;each&#160;class</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading&#160;Symbol</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">registered</b></p></td></tr><tr><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w" name="dei:Security12bTitle" id="Tc_hXyz-MrP-USbBjkwz2QL1g_1_0">American Depositary Shares, each representing 6 Ordinary Shares, par value &#163;0.001 per share</ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w" name="dei:TradingSymbol" id="Tc__XZIvw8OgEWISOtuRjcZTg_1_2">ADAP</ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The <ix:nonNumeric contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Narr_o8VDxFgVE0-Fg2VtHLtLag">Nasdaq</ix:nonNumeric> Capital Market</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 18pt 0pt 0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_rHdD2-5i_0a4243_I4_Qfw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_067e50a0_9bfb_4151_bf0f_6b155baffbab"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;">On September 6, 2025, Adaptimmune Limited, a subsidiary of Adaptimmune Therapeutics plc (the &#8220;Company&#8221;), entered into a consulting agreement with CJH Financial Limited (the &#8220;Consulting Agreement&#8221;) providing for the engagement of Christopher Hill as the Company&#8217;s Chief Financial Officer (&#8220;CFO&#8221;) effective from September 10, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Under the terms of the Consulting Agreement, the services provided by Mr. Hill include responsibility for the Company&#8217;s accounting and finance functions and Mr. Hill will represent the Company&#8217;s accounting function internally and externally. His other key responsibilities will include liaison with the Company&#8217;s independent auditors in relation to the Company&#8217;s quarterly reports on Form 10-Q and its annual report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mr. Hill is providing services to the Company as an independent contractor. The Consulting Agreement may be terminated by the Company or CJH Financial Limited upon 30 days&#8217; prior written notice by either party in the event of a material breach by the other party that is curable. If such material breach is not curable, the non-breaching party may terminate the Consulting Agreement immediately upon written notice to the breaching party. Pursuant to the Consulting Agreement, CJH Financial Limited will receive payment on the basis of &#163;2,200 (equivalent to approximately $2,968) per day as compensation for provision of Mr. Hill&#8217;s services as CFO verified by timesheets approved by the Company. Mr. Hill is not eligible to receive a bonus or for the award of share options. <span style="white-space:pre-wrap;">The foregoing summary of the Consulting Agreement is qualified in its entirety by reference to the complete text of the agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mr. Hill, age 45, has over 10 years experience of serving in chief financial officer and chief operating officer roles in public and private life science companies. Since September 2021, he has served as Chief Financial Officer and Chief Operating Officer (&#8220;COO&#8221;) of Istesso Limited, a private drug development company with pre-clinical to phase IIb assets developing new therapies in auto-immune and fibrotic diseases. He will step down from his CFO and COO roles with Istesso Limited on September 9, 2025. Previously, Mr. Hill served as part-time Chief Financial Officer of Ixaka Limited, a private cell therapy company, from April 2020 through September 2021 and as Finance Director of OxSonics Therapeutics Limited, a private clinical stage therapeutics company developing improved drug delivery solutions to solid tumour cancers, from March 2019 through September 2021. He also previously served as part-time Chief Financial Officer of Luke Hughes and Company Limited, a private furniture manufacturer, from March 2018 through June 2019 where he oversaw a corporate restructure. Mr. Hill served as Chief Financial Officer and a member of the Board of Directors of Oxford Pharmascience Group Plc, formerly a publicly listed drug development company on AIM focused on gastro-safe NSAIDs, from October 2013 through January 2018. Mr. Hill had responsibility for the financial, legal and HR functions within the group and for AIM and other regulatory reporting. During his tenure, the company underwent a demerger, and its operations were spun out into Abaco Capital (AIM: ABAA) and private company, Oxford Pharmascience Limited. His other prior roles include serving as Group Financial Controller at Ora Capital Partners Limited, previously an AIM-listed investment vehicle, from July 2010 through October 2013, and as Audit Senior at international audit, professional services and consulting firm, Grant Thornton UK LLP, from June 2005 to June 2010. He currently serves as a director of private companies, Connexion Therapeutics Group Limited and CJH Financial Limited. Mr. Hill is a chartered accountant and holds a B.A. degree in Economics and Public Policy from Leeds Metropolitan University.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There are no family relationships between Mr. Hill and any director or executive officer of the Company, and the Company has not entered into any transactions with Mr. Hill that are reportable pursuant to Item 404(a) of Regulation S-K. Except as described above, there are no arrangements or understandings between Mr. Hill and any other persons pursuant to which he was selected as CFO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*Compensation paid to Mr. Hill is denominated in pounds sterling. The amount for Mr. Hill above has been converted based on the pound sterling/U.S. dollar exchange rate of (&#163;1/$1.34926).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">(d)&#160; Exhibits.</p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:86%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:bottom;width:2.49%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description&#160;of&#160;Exhibit</b></p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="adap-20250906xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consulting Agreement dated as of September 6, 2025 by and between Adaptimmune Limited and CJH Financial Limited.</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:14pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;background:#ffffff;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:96.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ADAPTIMMUNE THERAPEUTICS PLC</p></td></tr><tr><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: September 8, 2025</p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Margaret Henry</p></td></tr><tr><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Margaret Henry</p></td></tr><tr><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate Secretary</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>adap-20250906xex10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 9/8/2025 02:56:51 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THIS CONSULTING AGREEMENT </b>(the &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;) is made the last date signed below (&#8220;<b style="font-weight:bold;">Effective Date</b>&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BETWEEN:</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Adaptimmune Limited, a company registered in England and Wales (Registered number: 06456741) with offices at 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4RX, UK (<b style="font-weight:bold;">&#8220;Adaptimmune&#8221;)</b>, on behalf of itself and its affiliates and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">CJH Financial Limited, a company registered in England and Wales (Registered number: 12872681) with registered office at 123 Hallgate, Cottingham, East Riding Of Yorkshire, England, HU16 4DA, UK and to be represented by Chris Hill (the &#8220;<b style="font-weight:bold;">Consultant</b>&#8221;).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW IT IS HEREBY AGREED </b>as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">DEFINITIONS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 28.35pt;">In this Agreement (unless it is expressly otherwise provided or the context otherwise requires) the following words and expressions shall have the following meanings:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">&#8220;<b style="font-weight:bold;">Confidential Information</b>&#8221; shall mean:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:64.1pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:13.9pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">any and all information concerning the scientific, technical or clinical data, business plans, Intellectual Property, customers, suppliers, associates, consultants or employees of Adaptimmune or its affiliated companies; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:63.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:14.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">any information which is of a confidential nature or is given or received or discovered in circumstances in which the Consultant knows or should reasonably have concluded that the information will be regarded by Adaptimmune as confidential including information provided by the Consultant to Adaptimmune.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">&#8220;<b style="font-weight:bold;">Expenses</b>&#8221; means the out-of-pocket expenses reasonably incurred by the Consultant in connection with the performance of the Services and in accordance with Adaptimmune&#8217;s expenses policy.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">&#8220;<b style="font-weight:bold;">Fee</b>&#8221; means the amount set out in clause 3, or such other rate as Adaptimmune and the Consultant may agree in writing from time to time.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">&#8220;<b style="font-weight:bold;">Intellectual property</b>&#8221; means all forms of intellectual property including, without limitation, patents, rights in know-how and confidential information, copyrights, designs, trademarks and any applications for the same.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">&#8220;<b style="font-weight:bold;">Services</b>&#8221; means the provision of services by Consultant to Adaptimmune during the Term of this Agreement, as described in each SOW referencing this Agreement and as may be entered from time to time between Consultant and Adaptimmune upon mutual written agreement. A first SOW detailing certain Services is attached hereto as Exhibit 1.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.6</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">&#8220;<b style="font-weight:bold;">Statement of Work</b>&#8221; or &#8220;<b style="font-weight:bold;">SOW</b>&#8221; means a proposal referencing this Agreement which details the Services, Fees, Expenses, and other details of the work to be performed, such SOW to be mutually executed by the Parties to be valid.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">APPOINTMENT AND TERM</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Consultant agrees to perform the Services using reasonable care, skill and diligence, in accordance with the highest professional standards and in accordance with any reasonable instructions provided by Adaptimmune. The Consultant will perform the Services in accordance with all applicable laws, rules and regulations, and in accordance with all applicable Adaptimmune policies including corporate governance, ethics policies, and insider trading policies of Appendix 1; and the data processing provisions of Appendix 2.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The days on which the Consultant performs the Services shall be agreed in advance with Adaptimmune. Save as provided in any Statement of Work, Adaptimmune does not make any guarantee that a certain number of days of Services will be approved in any particular time period.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:0.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Consultant shall ensure that the individuals performing the Services keep a record of all things done in relation to the provision of the Services and at Adaptimmune&#8217;s request shall make this available for inspection and provide copies to Adaptimmune.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">FEE</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Adaptimmune will pay the Consultant for Services in accordance with the payment details of each mutually executed SOW referencing this Agreement. No additional or further consideration will be payable by Adaptimmune in relation to the performance of the Services to the Consultant unless prior approval is obtained from Adaptimmune. The total Fees (plus reasonable Expenses, as detailed below) payable to the Consultant for the Services shall not exceed, and the Consultant shall not bill Adaptimmune for Fees in excess of, any preapproved total in each mutually executed SOW, in each case without Adaptimmune&#8217;s prior written consent.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Consultant will provide Adaptimmune with an invoice for such Services in accordance with each SOW, together with supporting timesheets or evidence of time incurred (if applicable): (i) upon completion of the Services, or (ii) on a monthly basis and within 14 days of calendar month end, as may be specified in each SOW. Adaptimmune will pay such invoices within thirty (30) days of receipt. All amounts under this Agreement are exclusive of VAT and any other relevant taxes, if applicable.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:0.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Consultant understands and accepts that the Consultant is not an employee of Adaptimmune. Consultant shall be responsible for making appropriate income tax contributions or other tax payments as required in relation to payment for the Services. The Consultant hereby indemnifies Adaptimmune in respect of any claims that may be made by the relevant authorities against Adaptimmune in respect of income tax demands or similar contributions relating to the provision of the Services by the Consultant.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">4</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">INDEPENDENT CONTRACTOR STATUS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 28.35pt;">The Consultant confirms that it is an independent contractor and that its performance under this Agreement will not entitle the Consultant or any individual performing the Services to any rights to any pension, insurance, car or other fringe benefits from Adaptimmune. The Consultant represents, confirms and warrants that it and the individuals performing the Services are free to perform the Services and there are no third party obligations or restrictions (including any restrictions imposed by a third party employer) including obligations or restrictions concerning providing services to others, confidentiality of proprietary information and assignment of inventions, ideas, patents or copyrights, and Consultant agrees that they will not do anything in the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 28.35pt;">performance of Services hereunder that would violate any such duty. The Consultant will notify Adaptimmune immediately if it becomes aware of any circumstances which might lead to a conflict of interest or breach of any professional conduct rules.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">5</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">EXPENSES</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:0.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">5.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Consultant shall be reimbursed for all pre-approved reasonable Expenses. The Consultant shall provide the Company with such receipts or other evidence of actual payment of the Expenses as shall be requested by Adaptimmune. Where the Consultant incurs a third-party Expense, Adaptimmune may at its option pay the relevant third party directly.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">6</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">CONFIDENTIALITY</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">6.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Consultant shall:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">6.1.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">use the Confidential Information disclosed to it exclusively to provide the Services.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">6.1.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">keep all Confidential Information that it may acquire in any manner confidential and not disclose it to any person or third party without the prior written consent of Adaptimmune.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">6.13</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">only disclose the Confidential Information to personnel who have a strict need to know the Confidential Information for the performance of the Services, who are made aware of the confidential nature of such information, and who are bound by confidentiality and non-use restrictions no less restrictive than those set forth in this Agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">6.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The foregoing restrictions on the Consultant shall not apply to any Confidential Information which the Consultant can establish by reasonable proof:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">6.2.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">was already in its possession before its disclosure under this Agreement; or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:27.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">6.2.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">is or becomes generally available to the public through no act or default on the part of the Consultant.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">6.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The confidentiality and non-use obligations under this Agreement shall survive any termination or expiry of this Agreement. The Consultant may also disclose Confidential Information where required to do so in accordance with applicable laws or court order, provided the Consultant first notifies in writing Adaptimmune and provides Adaptimmune (where possible) with a chance to apply for or obtain a protective order or equivalent confidentiality protection in relation to such information. The Consultant may only disclose Confidential Information required to be disclosed by the relevant applicable law or court order.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">6.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Upon the termination of this Agreement (for whatever reason) the Consultant shall upon request and within 30 days from receipt of request, deliver to Adaptimmune any Confidential Information or documentation encompassing Confidential Information which may be in its possession or under its control including all documents and any copies.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">7</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">INTELLECTUAL PROPERTY RIGHTS</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">7.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">All materials, equipment, documents, data compilations (in whatever form), software programs, electronic materials and other Confidential Information (&#8220;<b style="font-weight:bold;">Adaptimmune Property</b>&#8221;) that Consultant receives or makes during the term of this Agreement are</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 28.1pt;">and shall remain the property of Adaptimmune, and Consultant shall immediately return or procure the return of Adaptimmune Property (including any copies thereof) to Adaptimmune upon Adaptimmune&#8217;s request and/or upon the termination or expiration of this Agreement. Consultant shall not remove from the Adaptimmune offices any Adaptimmune Property except as authorized in writing by Adaptimmune. The obligation to return such property extends to anything received or made as a result of performing the Services for Adaptimmune.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">7.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">All Intellectual Property shall be owned by Adaptimmune where first created or reduced to practice in the performance of the Services. The Consultant hereby assigns and agrees to assign all Consultant&#8217;s right and title to such Intellectual Property to Adaptimmune. Consultant shall ensure it has in place with all individuals performing the Services sufficient written obligations to ensure that any Intellectual Property first created or reduced to practice in the performance of the Services is owned by Consultant and can be assigned by Consultant to Adaptimmune in accordance with this clause 7.2. Where necessary the Consultant agrees to execute and provide such further documentation as may be reasonably required by Adaptimmune to vest title to Intellectual Property in Adaptimmune in accordance with this clause. This clause shall survive any termination or expiry of this Agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">8</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">WARRANTIES</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">8.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Consultant warrants that Intellectual Property shall vest in Adaptimmune in accordance with clause 72 and that it is not subject to any agreements that would conflict or hinder such obligations to assign or transfer Intellectual Property to Adaptimmune.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">8.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Each Party warrants that it is fully authorized to execute and enter into this Agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">8.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Consultant represents and warrants that it has obtained, at its own expense, all necessary insurance for itself and all of its employees, contractors and agents (including the Consultant), including but not limited to workers&#8217; compensation insurance and a general liability policy to cover its contractual obligations contained herein, and it agrees to provide Adaptimmune with a certificate of insurance evidencing such coverage upon request.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">8.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Consultant represents and warrants that they have not been: (a) debarred under 21 U.S.C. &#167; 335a or equivalent foreign or local law provision; (b) on any clinical investigator enforcement list maintained by the FDA or any other governmental or regulatory authority or agency in any jurisdiction, or otherwise disqualified by any governmental or regulatory authority or agency in any jurisdiction from performing clinical research including the US Department of Health and Human Services Office of Inspector General (OIG) list of excluded individuals/entities (LEIE) database; (c) convicted of, or indicted for, an offense related to any health care program in any jurisdiction including any offenses identified on the OIG website; (d) excluded from, or otherwise rendered ineligible for, participation in any government-sponsored health care program in any jurisdiction (including being identified as having an active exclusion in the system for award management (http://www.sam.gov); or (e) engaged in any conduct rendering Consultant eligible for exclusion from participation in any government-sponsored health care program in any jurisdiction. Upon written request of Adaptimmune, Consultant shall promptly provide written confirmation that the foregoing representations remain accurate. Consultant shall promptly notify Adaptimmune in writing if any of the foregoing representations becomes untrue, or if any action or investigation is initiated, pending or threatened relating to the debarment, disqualification, conduct or exclusion of Consultant, and in such event Adaptimmune shall have the right to terminate this Agreement immediately upon written notice to Consultant.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">8.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Background Check</u><font style="white-space:pre-wrap;">.  Consultant represents and warrants that (a) it has complied with all legally required pre-employment obligations, (b) it has conducted criminal conviction record, drug testing and credit and other background searching of Consultant as requested by Adaptimmune, and (b) it has shared all results of such findings under clause (b) with Adaptimmune and has the relevant permission to share such personal data in accordance with applicable legislation.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">8.6</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Workplace Safety</u><font style="white-space:pre-wrap;">.  Consultant will perform the services in accordance with all applicable Adaptimmune policies, including all health and safety policies. Both parties shall also comply with all applicable laws, rules, and regulations, including those related to workplace safety and safe practices.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">9</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">TERMINATION</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">9.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">This Agreement shall commence on the Effective Date and shall continue until 31 December 2026 (the &#8220;Initial Term&#8221;). The Parties may mutually agree to extend this agreement in writing (such extensions together with the Initial Term being the &#8220;Term&#8221;).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">9.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">This Agreement may be terminated by either Party on provision of thirty (30) days written notice in the event of a material breach by the other Party, provided such breach is curable. If such material breach is not curable, the non-breaching Party may terminate this Agreement immediately upon written notice to the breaching Party.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">9.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Either Party may also terminate this Agreement, on provision of seven (7) days written notice, in the event that the other Party becomes insolvent, makes a voluntary arrangement with creditors or has an administrator or receiver appointed over any or all of its assets or is otherwise unable to pay its debts or where the Consultant is adjudicated bankrupt.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">9.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Termination of this Agreement shall not affect any provisions or clauses which are expressed to survive termination or expiry of this Agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">9.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Consultant acknowledges that a breach or threatened breach of this Agreement will result in irreparable and continuing damage to Adaptimmune. In the event of a breach or threatened breach, Adaptimmune shall be entitled to injunctive relief by a court of competent jurisdiction, in addition to such other relief as may be proper whether at law or in equity.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">10</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">ENTIRE AGREEMENT</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">10.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">This Agreement, together with the Appendices and any mutually executed SOWs referencing this Agreement, represents the entire agreement and understanding between the Parties relating to the provision of the Services during the term of this Agreement. Both Parties confirm that they have not relied on any warranties or representations other than those set out explicitly in this Agreement in entering into this Agreement. Nothing in this clause will exclude any liability or remedy for fraud or fraudulent misrepresentation. This Agreement shall not be modified except with the mutual written consent of the Parties.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">11</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">GENERAL</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">11.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Consultant may not assign this Agreement to any third party without the prior written consent of Adaptimmune. Any attempted or purported assignment without the required consent will be void.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">11.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Consultant shall not issue any announcement or press release mentioning Adaptimmune and will not disclose to any third party the fact that Adaptimmune has engaged the Consultant for the Services, or the terms and conditions of this Agreement, in each case without the prior written consent of the Adaptimmune.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">11.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">This Agreement and any SOW hereunder may be executed in any number of counterparts, each of which may be executed by less than all of the Parties, all of which together will constitute one instrument and will be enforceable against the Parties. This Agreement and any SOW may be executed by facsimile signature or as a signed &#8220;PDF&#8221; (portable document file) (either by actual signature and scan, or any electronic signature complying with the U.S. federal ESIGN Act of 2000 (e.g., www.docusign.com)) attached to an electronic mail message or other transmission method, and any counterpart so delivered is deemed to have been duly and validly delivered and are valid, fully enforceable, and effective for all purposes without a manually executed original.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">11.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">This Agreement shall be construed in accordance with and shall be subject to the laws of England without regard to its principles of conflicts of law, and the Parties hereby submit to the exclusive jurisdiction of the courts of England.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the undersigned, agreeing to be legally bound, have executed this Agreement as of the Effective Date (i.e., the last date signed below).</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td colspan="2" style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Adaptimmune Limited</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CJH Financial Limited</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Signed:</b></p></td><td style="vertical-align:bottom;width:44.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">/s/ Gavin Wood</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Signed:</b></p></td><td style="vertical-align:bottom;width:40%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">/s/ Christopher Hill</b></p></td></tr><tr><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Name:</b></p></td><td style="vertical-align:bottom;width:44.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Gavin Wood</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Name:</b></p></td><td style="vertical-align:bottom;width:40%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Christopher Hill</b></p></td></tr><tr><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Title:</b></p></td><td style="vertical-align:bottom;width:44.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Director</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Title:</b></p></td><td style="vertical-align:bottom;width:40%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Director</b></p></td></tr><tr><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Date:</b></p></td><td style="vertical-align:bottom;width:44.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">6 September 2025</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Date:</b></p></td><td style="vertical-align:bottom;width:40%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">5 September 2025</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">APPENDIX 1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ADAPTIMMUNE CODE OF ETHICAL BUSINESS CONDUCT </b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#8211;</b><b style="font-weight:bold;"> FOR THIRD PARTIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Introduction</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Adaptimmune is a clinical-phase company in the gene cell therapy arena. We strive to put patients at the very heart of our business. We are committed to working in an honest and ethical way and providing a working environment that respects the rights of our employees, consultants and contractors. We require that third parties working with Adaptimmune or providing services to Adaptimmune agreed to comply with our ethical business standards, to the extent in each case such standards are applicable to the work being performed by the third parties. Those standards are set out below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Applicable laws and Regulations</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect all third parties to and to procure that their employees, consultants and sub-contractors (<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</font>Applicable Individuals<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</font>):</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Always act with integrity and honesty and protect any Party<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8217;</font>s public image and reputation in relationships with customers, competitors, suppliers, business partners and staff</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Promptly raise any concerns about possible unethical or illegal conduct</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Be free from actual or potential conflicts of interest that might influence, or appear to influence their judgment or actions when performing duties on behalf of the Parties</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Provide accurate and reliable information, safeguard Adaptimmune<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8217;</font>s confidential information, and respect the confidential information of other parties.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Business should be conducted in compliance with applicable laws, rules and regulations. No Applicable Individuals or third parties shall engage in any unlawful activity in performing his or her day-to-day duties, nor instruct others to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Anti-Corruption and Anti-Bribery</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In complying with this Code of Ethical Business Conduct, all third parties and Applicable Individuals will respect the requirements applicable to anti-bribery and anti-corruption, including requirements imposed under the US Foreign Corrupt Practices Act 1977 (<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;</font>FCPA<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8221;</font>) and the UK Bribery Act 2010. In particular, no Applicable Individual shall seek to bribe any other individual, facilitate the giving of a bribe to any other individual or accept any bribe or facilitate the acceptance of any bribe from any other individual. Please note facilitate payments are not exempt from this requirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Research and Development; Quality</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Patient Safety is of the utmost importance for Adaptimmune. We strive to carry out our research and development, manufacture, storage and distribution of our SPEAR T-cells in compliance with applicable laws and best practices (such as, but not limited to, GCP, GLP. GMP). Any research and development should be carried out by Applicable Individuals with integrity and accuracy and in each case in accordance with all applicable standard operating procedures applicable to them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Human Rights and anti-slavery legislation</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect all third parties to act in accordance with all legislation relating to human rights. In addition, services should not be performed in breach of anti-slavery legislation or using any child-labour.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conflict of Interest</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A conflict of interest occurs when an Applicable Individual<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8217;</font>s private interest interferes, or appears to interfere, in any way with the interests of Adaptimmune as a whole. Any Applicable Individual should actively avoid any conflict of interest that may impact such Applicable Individual<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8217;</font>s ability to act in the interests of Adaptimmune or that may make it difficult to perform the Applicable Individual<font style="font-family:'Calibri','Helvetica','sans-serif';">&#8217;</font>s work objectively and effectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employment Principles/Corporate Social Responsibility</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Adaptimmune is firmly committed to providing equal opportunity in all aspects of employment and we support and respect the protection of internationally adopted human and labour rights. We will not tolerate any illegal discrimination or harassment based on race, ethnicity, religion, gender, age, national origin or any other protected class.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SEC-listing company</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Adaptimmune is listed on the NASDAQ Global Select market. As a result, it has obligations under SEC legislation and regulations. In working with Adaptimmune you may be party to confidential information of Adaptimmune which may be potentially price sensitive. You should advise individuals that insider trading rules may apply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reporting Concerns</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If you or any Applicable Individuals have concerns or questions about possible ethical misconduct, or suspect a possible violation of and of the standards set out in this code of conduct, please contact your appropriate relationship manager at Adaptimmune. Alternatively, if you or any Applicable Individual wish to keep the complaint anonymous, you may:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">use the anonymous online submission form at: <i style="font-style:italic;">http://adaptimmune.ethicspoint.com</i>;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">leave an anonymous phone message at UK Phone Number <font style="font-family:'Calibri','Helvetica','sans-serif';">&#8211;</font> 0-800-89-0011 followed by (833) 627-1022, or US Phone Number <font style="font-family:'Calibri','Helvetica','sans-serif';">&#8211;</font> (833) 627-1022; or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">deliver the complaint anonymously via post, courier or hand delivery to the Company Secretary or the Chief Executive Officer or the Chairman of the Audit Committee at: Adaptimmune, 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RX, United Kingdom.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">APPENDIX 2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">DATA PROCESSING TERMS</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">1.1</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">In this Exhibit:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">Adaptimmune is the &#8220;Controller&#8221; and Consultant is the &#8220;Processor&#8221;; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">the types of Personal Data and categories of Data Subject which will be processed, the nature and purpose of that processing and the duration of that processing are as set out below:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:84.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">(i)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">Personal Data capable of identifying any of Adaptimmune&#8217;s employees, consultants, contractors, third party suppliers, CRO&#8217;s and other third parties with whom Adaptimmune has a business relationship, clinical trial patient information and details.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">&#8220;Data Protection Legislation&#8221; in this Exhibit refers to all applicable privacy and data protection laws including the General Data Protection Regulations ((EU) 2016/679) (GDPR) and any applicable national implementing laws, regulations and secondary legislation in England and Wales relating to the processing of personal data and the privacy of electronic communications, as amended, replaced or updated from time to time, including the Privacy and Electronic Communications (EC Directive) Regulations 2003 (SI 2003/2426) (Privacy Regulations) as amended by the Privacy and Electronic Communications (EC Directive) (Amendment) Regulations 2011 (SI 2011/1208), the Privacy and Electronic Communications (EC Directive) (Amendment) Regulations 2015 (SI 2015/355) and the Privacy and Electronic Communications (EC Directive) (Amendment) Regulations 2016 (SI 2016/524).</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:9.5pt;">(d)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:9.5pt;">&#8220;Personal Data&#8221; and &#8220;Data Subject&#8221; shall have the meanings given to them under the Data Protection Legislation.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">1.2</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">In relation to the processing of Personal Data, Consultant shall:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">only process Personal Data in accordance with Adaptimmune&#8217;s written instructions from time to time (which may be specific instructions or standing instructions of general application in relation to the Services, whether set out in this Agreement or otherwise notified to the Consultant), unless such processing is required by any law (other than contract law) to which the Consultant is subject, in which case the Consultant shall (to the extent permitted by law) inform Adaptimmune of that legal requirement before carrying out the processing;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">immediately notify Adaptimmune if it considers that Adaptimmune&#8217;s instructions are in breach of the GDPR or other EU member state laws; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">keep a written record of all such processing activities which shall include the information required to be kept under Article 30(2) of the GDPR namely name of privacy officer, Personal Data type held on behalf of Adaptimmune, type of processing being undertaken on behalf of Adaptimmune, any transfers of Personal Data to any country outside of the European Union or UK, the technical and security measures in place at Consultant to preserve security of Personal Data.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">1.3</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">In relation to the security and confidentiality of the Personal Data, the Consultant shall:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">ensure that it has in place appropriate technical and organisational measures to ensure a level of security for the Personal Data which is appropriate to the risks to individuals that may result from the accidental or unlawful destruction, loss, alteration, unauthorised disclosure of, or access to the Personal Data;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">in addition to the confidentiality obligations in the Agreement, if any:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:84.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">(i)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">ensure that only those of the Consultant&#8217;s personnel who need to have access to the Personal Data are granted access to such data and only for the purposes of the performance of this Agreement and all of the Consultant&#8217;s personnel required to access the Personal Data are informed of the confidential nature of the Personal Data, comply with the obligations set out in this Exhibit, and are bound by appropriate confidentiality obligations when accessing the Personal Data; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:84.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">(ii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">not publish, disclose or divulge any of the Personal Data to any third party (including for the avoidance of doubt the Data Subject itself) unless directed to do so in writing by Adaptimmune;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">not modify, amend or alter the contents of the Personal Data unless specifically authorised in writing by Adaptimmune.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">1.4</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">If the Consultant becomes aware of a Personal Data breach, it shall notify Adaptimmune without undue delay on becoming of aware of such a breach.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">1.5</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">Consultant shall notify Adaptimmune within five Business Days upon receiving the following:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">a request from a Data Subject to have access to that person&#8217;s Personal Data; or</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">a complaint or request relating to Adaptimmune&#8217;s obligations under the Data Protection Legislation; or</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">any other communication relating directly or indirectly to the processing of any Personal Data in connection with this agreement.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">1.6</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">Consultant shall provide Adaptimmune with full co-operation and assistance in order to enable Adaptimmune to comply with its obligations under the Data Protection Legislation in relation to:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">Adaptimmune&#8217;s obligations in relation to responding to Data Subject requests;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">the security of the Personal Data;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">notifying Personal Data breaches to the relevant supervisory authority;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">(d)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:9.5pt;">communicating personal data breaches to the Data Subject; and</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">impact assessments and related consultations with supervisory authorities or regulators.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">1.7</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Consultant shall:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">make available to Adaptimmune all information that Adaptimmune requests from time to time to enable Adaptimmune to verify that the Consultant is in compliance with its obligations in this Exhibit; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">permit Adaptimmune or its external advisers to inspect and audit the Consultant&#8217;s data processing activities and those of its agents, subsidiaries and Sub-contractors (to the extent Consultant is reasonably able to procure such third-party access).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">1.8</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Consultant shall not engage or authorise a sub-contractor to process the Personal Data unless:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:84.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">it has obtained the prior written consent of Adaptimmune (which may be granted or withheld in Adaptimmune&#8217;s sole discretion) before transferring the Personal Data to any sub-contractors in connection with the provision of the Services; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:84.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the sub-contractor has either entered into a direct contract with Adaptimmune or a contract with the Consultant which incorporates the provisions equivalent to those in this agreement in relation to confidentiality, data protection and security, and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">1.9</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">In relation to transfers of Personal Data to areas outside the European Economic Area (EEA):</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the Consultant shall not transfer any Personal Data outside the EEA without Adaptimmune&#8217;s prior written consent; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">if Adaptimmune consents to any transfers pursuant to clause 1.9(a), Consultant shall ensure that the following conditions are met in relation to such transfers:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:84.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the Consultant complies with its obligations under the Data Protection Legislation by ensuring that there is an adequate level of protection to any Personal Data that is transferred (including as relevant model clauses or adoption of Privacy Shield as appropriate);</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:84.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">that there are appropriate safeguards in place in relation to that transfer;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:84.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">that Data Subjects have enforceable rights and effective legal remedies; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:84.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(iv)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">that the Consultant shall comply with any other reasonable instructions as notified to it by the Adaptimmune in relation to such transfers.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">1.10</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Adaptimmune acknowledges that the Consultant is reliant on Adaptimmune alone for direction as to the extent the Consultant is entitled to use and process the Personal Data. Consultant shall be entitled to relief from liability in circumstances where a Data Subject makes a claim or complaint with regards to the Consultant&#8217;s actions to the extent that such actions directly result from instructions received from Adaptimmune.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">1.11</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">On the expiry or termination of this Agreement, the Consultant shall notify Adaptimmune of the Personal Data that it holds. Promptly following such expiry or termination, and unless otherwise instructed in writing by Adaptimmune or continued storage is required by Consultant to comply with Applicable Laws, Consultant shall securely and permanently destroy all copies of Personal Data in its possession or control (other than any copy transferred to Adaptimmune in accordance with Adaptimmune&#8217;s request).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">1.12</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Consultant shall, at all times during and after the term of this Agreement, indemnify Adaptimmune and keep Adaptimmune indemnified against all losses, damages, costs or expenses and other liabilities (including legal fees) incurred by, awarded against or agreed to be paid by Adaptimmune arising from any breach of the Consultant&#8217;s obligations under this Exhibit except and to the extent that such liabilities have resulted directly from Adaptimmune&#8217;s instructions.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">STATEMENT OF WORK TO THE CONSULTANCY AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Scope of the Services:</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To perform Chief Financial Officer services for Adaptimmune including:</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Overall strategic direction of Adaptimmune, subject to any required decisions of Board, including in relation to ongoing status of the Company and strategic options for assets of business</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Overall management of business including ongoing clinical trials</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Overall management of transition services with USWM</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Management of corporate teams including specified line reports</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Management of any required corporate activities including any transaction, de-listing or dissolution requirements</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Liaising with investors and investor community as reasonably needed</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Updating Board of Directors as required</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To perform CFO (including as section 16 officer) services for Adaptimmune including responsibility for preparation of all financial accounts and SEC filings on behalf of Adaptimmune</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The parties have agreed that initially the services will be performed by Chris Hill. Any changes to the individual performing services will be mutually agreed between the parties. To the extent any changes cannot be mutually agreed within the later of (a) 30 days of Consultant providing an alternative and (b) date Chris Hill ceases to provide services under this SOW, this SOW shall automatically terminate and there will be no further obligation on either party in relation to this SOW following the date of such termination.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Term of the Services:</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">From 10</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;vertical-align:top;">th </sup><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">September 2025 (&#8220;Start Date&#8221;) until 31</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;vertical-align:top;">st</sup><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> December 2026, unless extended or earlier terminated as provided in the Agreement.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Contract Price</b> (excluding expenses and VAT):</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#163;2,200 per day</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The estimated total amount to be paid by Adaptimmune to </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consultant Company </font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">shall not exceed </b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#163;500,000 </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">without Adaptimmune&#8217;s written authorization accompanied by an updated SOW or new purchase order corresponding to the additional cost.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Consultant Company will provide Adaptimmune with an invoice for such Services monthly. Adaptimmune will pay such invoices within thirty (30) days of receipt. All amounts under this SOW are exclusive of VAT and any other relevant taxes, if applicable.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">For a period of six months starting on the Start Date, Adaptimmune agrees to pay for at least 3 days per week in relation to the provision of services under this SOW. Thereafter the parties will mutually agree the days required by Consultant to perform the services.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other Terms</b>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font>Work Location. Consultant will primarily perform the Services from their office address and is entitled to perform the Services from any appropriate setting, except as may be otherwise directed by Adaptimmune in advance. Should Adaptimmune require Consultant to perform work from Adaptimmune&#8217;s office, Consultant will be reimbursed for travel to and from Adaptimmune&#8217;s office and any reasonably necessary accommodation expenses as per Adaptimmune&#8217;s applicable policies. Should Consultant be required to travel to other locations in order to perform the Services, all travel expenses will be recharged at cost to Adaptimmune so long as properly incurred, documented by Consultant and included in a monthly invoice and in each case in accordance with Adaptimmune&#8217;s applicable policies. Adaptimmune may choose to make such travel bookings for Consultant and pay for such travel costs and expenses direct. All travel expenses over &#163;1,000 are to be agreed in advance by</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Adaptimmune. Consultant will be paid specific fees for the Services performed by the Consultant, as detailed herein, and shall not be entitled to claim reimbursement for, or expense costs to, Adaptimmune for expenses associated with a home-based or remote working setup, including, without limitation, costs associated with electricity or other utilities, a home office phone, Internet access, office equipment, office furniture, and use of the space. In the event that applicable law creates a right for the Consultant to be reimbursed or receive payment for such expenses, the parties agree that the Consultant will be responsible for all such costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font>Equipment. Consultant hereby acknowledges that they may be provided Adaptimmune-issued equipment and materials (e.g., laptop) (&#8220;Equipment&#8221;) solely to perform the Services on behalf of Adaptimmune. Such equipment may utilize software that identifies and records the user (directly or indirectly), including for security and software update purposes. Consultant represents and warrants that it has obtained the authorization and consent from the individual performing the Services to enable Adaptimmune&#8217;s performance of such activities and its third-party vendors pursuant to applicable data privacy regulations. Consultant shall ensure that the Consultant and each individual performing the Services: (a) uses the Equipment only to perform the Services and for no other use; and (b) complies with all Adaptimmune policies in relation to information security and use of the Equipment. Consultant shall not knowingly enable any Disabling Device on the Equipment or any Adaptimmune networks, servers or systems accessed via the Equipment. For purposes of this Letter Agreement, &#8220;Disabling Device&#8221; means any programs, mechanisms, programming devices, malware or other computer code (i) designed to disrupt, disable, harm, or otherwise impede in any manner the operation of any software program or code, or any computer system or network (commonly referred to as &#8220;malware&#8221;, &#8220;spyware&#8221;, &#8220;viruses&#8221; or &#8220;worms&#8221;); (ii) that would disable or impair the operation thereof or of any software, computer system or network in any way based on the elapsing of a period of time or the advancement to a particular date or other numeral (referred to as &#8220;time bombs&#8221;, &#8220;time locks&#8221;, or &#8220;drop dead&#8221; devices); (iii) is designed to or could reasonably be used to permit a party or any third party to access any computer system or network (referred to as &#8220;trojans&#8221;, &#8220;traps&#8221;, &#8220;access codes&#8221; or &#8220;trap door&#8221; devices); or (iv) is designed to or could reasonably be used to permit a party or any third party to track, monitor or otherwise report the operation and use of any software program or any computer system or network by the other party or any of its customers. Consultant will promptly notify Adaptimmune of any knowledge of any Disabling Device on the Equipment, or of any risk to Adaptimmune networks, servers or systems. Consultant hereby acknowledges that they will cooperate to promptly return such equipment to Adaptimmune upon any termination or expiration of this Assignment Letter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This SOW may be executed in any number of counterparts, each of which may be executed by less than all of the Parties, all of which together will constitute one instrument and will be enforceable against the Parties. This SOW may be executed by facsimile signature or as a signed &#8220;PDF&#8221; (portable document file) (either by actual signature and scan, or any electronic signature complying with the U.S. federal ESIGN Act of 2000 (e.g., www.docusign.com)) attached to an electronic mail message or other transmission method, and any counterpart so delivered is deemed to have been duly and validly delivered and are valid, fully enforceable, and effective for all purposes without a manually executed original.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the undersigned, agreeing to be legally bound, have executed this SOW as of the Effective Date (i.e., the last date signed below) subject to the terms and conditions of the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Adaptimmune Limited</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CJH Financial Limited</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Signed:</b></p></td><td style="vertical-align:bottom;width:41.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">/s/ Gavin Wood</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Signed:</b></p></td><td style="vertical-align:bottom;width:42.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">/s/ Christopher Hill</b></p></td></tr><tr><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:41.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:42.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Name:</b></p></td><td style="vertical-align:bottom;width:41.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Gavin Wood</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Name:</b></p></td><td style="vertical-align:bottom;width:42.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Christopher Hill</b></p></td></tr><tr><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:41.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:42.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Title:</b></p></td><td style="vertical-align:bottom;width:41.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Director</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Title:</b></p></td><td style="vertical-align:bottom;width:42.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Director</b></p></td></tr><tr><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:41.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:42.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Date:</b></p></td><td style="vertical-align:bottom;width:41.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">6 September 2025</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Date:</b></p></td><td style="vertical-align:bottom;width:42.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">5 September 2025</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>adap-20250906.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  11.0.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 9/8/2025 2:56:58 PM-->
<!--Modified on: 9/8/2025 2:56:58 PM-->
<xsd:schema xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt-roles="http://fasb.org/srt-roles/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:attributeFormDefault="unqualified" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:srt="http://fasb.org/srt/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:country="http://xbrl.sec.gov/country/2025" targetNamespace="http://www.adaptimmune.com/20250906" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:adap="http://www.adaptimmune.com/20250906" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:rxp="http://xbrl.sec.gov/rxp/2025" xmlns:snj="http://xbrl.sec.gov/snj/2025" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:cyd-8k-sub="http://xbrl.sec.gov/cyd-8k-sub/2025" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2025" xmlns:spac-lab="http://xbrl.sec.gov/spac-lab/2025" xmlns:spac-despac="http://xbrl.sec.gov/spac-despac/2025" xmlns:spac-reg="http://xbrl.sec.gov/spac-reg/2025" xmlns:spac="http://xbrl.sec.gov/spac/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="adap-20250906_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adap-20250906_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="adap_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>adap-20250906_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  11.0.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 9/8/2025 2:56:58 PM-->
<!--Modified on: 9/8/2025 2:56:58 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="adap-20250906.xsd#adap_DocumentAndEntityInformationAbstract" xlink:label="adap_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="adap_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adap_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Country</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>adap-20250906_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  11.0.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 9/8/2025 2:56:58 PM-->
<!--Modified on: 9/8/2025 2:56:58 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="adap-20250906.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adap-20250906.xsd#adap_DocumentAndEntityInformationAbstract" xlink:label="adap_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638929402187101827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_638929402187101827" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638929402187101827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_638929402187101827" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638929402187101827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_638929402187101827" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638929402187101827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_638929402187101827" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638929402187101827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638929402187101827" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638929402187101827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638929402187101827" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638929402187101827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_638929402187101827" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638929402187101827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine2_638929402187101827" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638929402187101827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_638929402187101827" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638929402187111810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_638929402187111810" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry_638929402187111810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCountry_638929402187111810" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638929402187111810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_638929402187111810" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638929402187111810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_638929402187111810" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638929402187111810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_638929402187111810" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638929402187111810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_638929402187111810" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638929402187111810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_638929402187111810" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638929402187111810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638929402187111810" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638929402187111810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_638929402187111810" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638929402187111810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_638929402187111810" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638929402187121794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_638929402187121794" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638929402187121794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638929402187121794" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638929402187121794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_638929402187121794" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638929402187121794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adap_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_638929402187121794" order="23" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 06, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adap_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep.  06,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-37368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ADAPTIMMUNE THERAPEUTICS PLC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">60 Jubilee Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Milton Park<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Abingdon, Oxfordshire<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">OX14 4RX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">1235 430000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing 6 Ordinary Shares, par value &#163;0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADAP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001621227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adap_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adap_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="adap-20250906x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>adap-20250906.xsd</File>
    <File>adap-20250906_lab.xml</File>
    <File>adap-20250906_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="adap-20250906x8k.htm">adap-20250906x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "adap-20250906x8k.htm": {
   "nsprefix": "adap",
   "nsuri": "http://www.adaptimmune.com/20250906",
   "dts": {
    "schema": {
     "local": [
      "adap-20250906.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "adap-20250906_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "adap-20250906_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "adap-20250906x8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adap-20250906x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adap-20250906x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "adap_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adaptimmune.com/20250906",
     "localname": "DocumentAndEntityInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Adress Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001558370-25-011925-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-25-011925-xbrl.zip
M4$L#!!0    ( *> *%N>>*'F)00  $T/   1    861A<"TR,#(U,#DP-BYX
M<V2U5]MNXS80?2_0?V#U+DMVZB VXBPVW;8(D+1%-@OD;4&3M,U=B51):FW_
M?8>4*)NZQ5NTR$-DGC,WS@PYO'UWR#/TC2G-I5A%TTD:(2:(I%QL5U&I8ZP)
MY]&[NQ]_N/TICE_OGQ\1E:3,F3"(*(8-HVC/S0Z]R*+  CTQI7B6H7O%Z98A
M- 65\'>%XKC6<8\UR$B!G++99-H@O]3ZI%BB17*3S-+9',V6\^OE_ ;]]=3P
MGL"]#7^+>-!TJ<F.Y1A!C$(O#YJOHITQQ3))]OO]9'\UD6H+PNDT>7UZ_.BX
M,1?:8$%85$O!'IACP70CNL%Z[00]XLR?T;<8%[UL"[3)2F8#NAT2THT* CBL
M5>9#6"2 >B)EIT@=23,RV<IO"0"!1JW,4'0-% @<,BZ^]NWB=+%8) [U5%(J
M!:5T[/?$HX%VP;:V $:"M)N2U+3S( :VL8'"J$VA^KVR2!@OH'S0GZND72W8
M&,77I6&_295_8!M<9@;Z2/Q=XLS5K"=V]C'4:^$U-(JG*[899%\G@#9;B#G1
M_<$YJ)7-$1=>'\^2R0YDUZ_5(J%23=]NL[/<]68MS!<G ^GBI),M:D)N;7N>
M5&!3G;(41@T59P76N@U66V;^P#G3!28L" Y37!B>YZ5@$R)S)Y$NTNL(75 )
M+&/V' T(G4*A1K5:-$@5P(F%K>6?XW0:7TV;6J1GY]"XLW6219G/^G9OED*:
M#1.:KS,66QI3V,"-H>.9O3'\J5,H1BYIX!/SU/GF[:XW9WLRPJ:G@Y"<M4V8
M8;;I5@[OK9SKJG)XTXJ'HE\G &'9BB\#92N^]-T9,5L/WQL6#(3(D0Z$=J1M
M8GSS-=;E>I!?XQTQO!D7J_ P:&B1.,,#0A[MBE#77"-2%:$KJ-AV1 K0CL@P
M/: R,K#! %1$F#(0<G,&%D(:UQ%NS:\6!1<;62_!HCW5E[:87Z!CD?WX]/PP
MVJ*N\C_4 Y?__U[07X7AYO@ VE7N[$:(@[L7,1M_O$>4;;C@SOL4&BA%,?(*
MSC^QH*C2AL[4W29M'6WU)<Q[?XH[]PU]KT&7D[3W2RU=4\8D"<Y(F?T+P9-G
MPW+UJD]-*V/^,GYF&^1&G*4]<5>1YGF1V2O:K>W<'6T3&/N#]3.$.X%J\A2K
M?^3&=<EN[U!MV*O BG2T=$8P4"(+I@R'P><T223_65C0P=\;%HBP[/^)YS9I
M-UN]$C:E:TD(32J#1.]E/C3:5:^(1TF<LA$1^ZMY0,1V*9[.X$:>@&GO[[@;
M_2/+A0YX 6MY_ITVNR^$/J-ZB&X_7'UTS-9#CK-[.J#Z#J;W:VT4)J8ZRFS%
M?;Z,7I6M&]5AME?P='TP++>-#%&40..FM!*_*UD6GLB! E-:K605&54"7<#;
M%:]M/5:_*R[4'I?TQ9FAI:H/7!MD56G55MW] U!+ P04    " "G@"A;'5_,
M,9(%  "Q/@  %0   &%D87 M,C R-3 Y,#9?;&%B+GAM;-6;_V_B-AC&?Y^T
M_^$]]LLF74A)U=,5M3U1KC=5H]?JX+33INED$@/6@HT<<]#_?G824Q+L\*V+
MC"JU 3]^_#[.)TX"Z=6'Y32&'Y@GA-'K1JMYU@!,0Q81.KYNS!,/)2$AC0\W
M/_]T]<;SOMU^Z4'$POD44P$AQTC@"!9$3&# 9C-$X0%S3N(8;CF)QAB@)2WE
MSSEX7NYQBQ+9AU%(S8)F:]72S?T8;<.E_]X/SH(+"-H7[]H7[^'I8:5[D.6-
MR#9A3.B_;?5K* <$&9,F[65"KAL3(69MWU\L%LW%>9/QL>Q_UO*_/?3ZX01/
MD4=H(A -<2/OI4P*W99#'NN.Y[X>0\M5:R16'=;%%W[6N))N6.<5M2XO+_VT
M54H3TD[2RGHL1"+=45N+ :M"O?*TS%-O>:W .V\UETG4D!,'D$\=&N*X)[<@
MK:,MGF?XNH&7 M,(1XW\7<YB7%&.:DYKRIR5-PL+AK'*Q+CVFW \NFZ@",T\
MM5?/+L_>J<)^4>]\_YB3UZ'1'15$/-_3$>/3=$XZPT1P% IME):?.>W:3^V2
MG?:SOPJC!NGP8B+$0UV$W-PR0;G"#YD$;B:\U%%W'W$VW2]"5@;;H]/W>!@?
MGKT0G..$S7EZW.S.QGK>???9JG;94ZU7F'I?^WN$N=&# *(19,/ VCCPMQ[I
MGZNLTKTH5@4D>@5(<-@<LQ]^A$FZ7JF-%/$4;_EBE7@@'4LS8FAV%%9;$,5D
MN<U!]*PE'DV8<JL1HB?,"9-'3O11GE(K0I9U)X"5,5J9KX+(<=#,M1Y-7&8K
ME[4(E'$-\&4KZ"<2X\_SZ1!S0V:#Q&'D;($T;>5V1T&SEGDH8_FI4CE"9ED;
M75_PF*AS,A6?T=2TLEEDSE-F#E8DK:AQFC9+J4<2]^(*RK8VZN[E/3&?,9Y>
M%O:%7$Z[;$X%?^ZRR [AME[.,[E3["*BE5V<)G:WRH\$N##(6TB' <8A'PK4
M6+51/4#+^TA>*I 1R3Y8V'+:MNN=)WE+U"+#%K'3]&ZK^4ANI3T4_>L^\7>B
M2,Y:DO_I$8I;ULDP:YV'M")B$5"#T&DXJ^H]$LS<\ZW> .4.C[2^570S7+#'
M1 2G"6:P*YC!B8$9_ ]@OG Y6+"ZN>S*S4<^8 NZ;18*RE-A<C.>D<@7V2GP
M:*CVM6A4UNJ"4YG7C>(32P2*_R*SRKLFB_A4@#2&-#)94)X"EN:"7XO,S!VD
M?;UW0?J8R^[ MAZ:*]FI %D*9EX>,\TI0%@N]=46QLRW!NS4$MSA&%E6P5*S
MPYB9@FB\UML<Q<I8XJ$XI>=5Y5;7XJ4>!HF?)HS:OVPQ2!RFR19($U5N=Y0J
M:YF'DI4:0NI8WV<N?W(B!*9=-IW.:?Z)3V)(:],YS%EE- V;4>0H<=6U'HI=
M[@I%VQK0Z[.8A$00.GY  G."3)F-(H>ALX?2Q&TJ',6MHM!#67NQ!.U9 VA/
M'"NXL=QQZ?,^ZL%&_C@:&<^EE6*'P=L>4@-H5SH*X@X%'PJDM/;"-6_(S"%U
MKQ_-^R298[X7H*8NIX.I-; %U@W]:2!K+_O5P,V&J)O?/@[G\OKAN14,!T3$
MIMM<@\1A/FV!5F?O4KNC_%G+/)2WU 78"%K!K\/?0/O7@-B (_5?*OWGZ9"9
MHI;;'8;+&$6356AT%"MSC0<SE;E!9E?C:G6W#">R9&QYLM B<QBLJF#EE6M=
MXRAFE:4>?.^1FX)VK??)PKLIYF-)^^^<+<1$7AS,$+5_"6%3.\S@#C&+7TD8
MI8X2N4O%1WY!H<TA<X?<OC9 N_(JDJ/X7EX_+O_ =C0W=<Y#:8E6Q+$D<AI$
M6ZU'(IC;0NH+TK@&^#KR[B52=S"?8C0V!"ZW.PR;,8J&K-#H*%SF&@^%:N4&
MRFX=I2O_9>2>W%+_QIV_E?>^^0]02P,$%     @ IX H6]T&1P"-!   7"H
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M(0_C81>/F,)0FD6#_,100B3+-A]&4L$?:1OW729VM2 V7,<4?4'9#5%W ,^
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M.'9E1$$:\<"K.;(5<^19U !@30$QUJ:;*JY7%"R/A$L!^,"T I(^]0D2_2R
M0%*'00R62QQ)7[UN4-.?9F)7 9H:J6_6ZQ_FM/94H)>2*^''K*LD;=MT(Y#.
M4;JK -]( L_XIH'6M^^ZR#H1.>)T"M$Q"(H'C#EC^HP\44%H)>$'QQL"NPI.
M&#*P(M"@%43^$KN"F#/]DR7[6JI^ZNB/@1A["#J-4I\048<4Q59\NV\S<7D.
M=3.V'NZ&,T/)=OA@#1:))NU9S^<>WH)QOD?V]X^G( GY4TNH9U)A5(72,*5E
MDZH+84@"73,Z<9XJ#M;_  (]-D:;=$Y/2CRGVX+0(<N,Z'FKDZ9W/N,0Z2N+
MRZ%A=,]W+>RPF:OG@-70?L--K0EK]P?X0NQT+'?]8SQQ-9'+W6<,QATP('(
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MS^H%9)20=03G8Q#+:&PVQAQG*JLU<3)W<&0!L@TSB= PNI;H=%LPLK=R3.#
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M2Y-X6A+)0O;$/E:-X <QF-HI0WQ(P0Y-D2AF7%C3NW@@&ZA:D'42T /0T*>
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MU/$6R"]T.;HL(Z#1,!5P9U/%6K7@C>/(!1(I$EU0U@;5TW4)B8+"/9&!E3,
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MVT6RR-.J642?5(R6K?*\FFO(!,39;,1R"K3%-_DFB2!^ "H_^1Q+M@'3!*8
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M2P$"% ,4    " "G@"A;'5_,,9(%  "Q/@  %0              @ %4!
M861A<"TR,#(U,#DP-E]L86(N>&UL4$L! A0#%     @ IX H6]T&1P"-!
M7"H  !4              ( !&0H  &%D87 M,C R-3 Y,#9?<')E+GAM;%!+
M 0(4 Q0    ( *> *%L/W[=<;AH  !>?   4              "  =D.  !A
M9&%P+3(P,C4P.3 V>#AK+FAT;5!+ 0(4 Q0    ( *> *%N?-"]9X$(  $<G
M @ 8              "  7DI  !A9&%P+3(P,C4P.3 V>&5X,3!D,2YH=&U0
52P4&      4 !0!- 0  CVP

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>adap-20250906x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="adap-20250906.xsd" xlink:type="simple"/>
    <context id="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001621227</identifier>
        </entity>
        <period>
            <startDate>2025-09-06</startDate>
            <endDate>2025-09-06</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w"
      id="Tc_58pe7063q0m0r0D_9NhQVQ_2_1">0001621227</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w"
      id="Tc_LS-i8fAZJUaDNZsmco3xZw_3_1">false</dei:AmendmentFlag>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w"
      id="Hidden_sChDiFw5FkehkAukQBvJMw">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:DocumentType
      contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w"
      id="Narr_LbTcta_tYE20g7G0DIGAdg">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w"
      id="Narr_MsjkMKVYEkqgVdF5Zmtf6A">2025-09-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w"
      id="Narr_auvOSjmgKkyoGXd3yxwugw">ADAPTIMMUNE THERAPEUTICS PLC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w"
      id="Tc_ZfAjvfG7lEWDuP2VdtidOA_1_0">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w"
      id="Tc_zhue9xRsVkGMKq_iHFxfSQ_1_2">1-37368</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w"
      id="Narr_LePotmiYzkyyn10bXKaisw">60 Jubilee Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w"
      id="Narr_oTPY53SGN0ek5ruIR8wW5g">Milton Park</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w"
      id="Narr_kvFhmtvvAkiFRxsFFNKGzA">Abingdon, Oxfordshire</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w"
      id="Narr_CxUgOQBt1U-ZqQpWWoQU1Q">OX14 4RX</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w"
      id="Narr_yMp4hFXDfkSXcyqGt0O5og">GB</dei:EntityAddressCountry>
    <dei:CityAreaCode
      contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w"
      id="Narr_hrlMBQLMPkyIe8EnHiNBtA">44</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w"
      id="Narr_FWNo0f6xUEeW3tl_0x3OeQ">1235 430000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w"
      id="Narr_VzFAY9KztkGCTSeUajjTqw">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w"
      id="Narr_vL6nLoZXsk-D2kM4neUjFw">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w"
      id="Narr_NtIKpyDxC0y8NEpKoksEQw">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w"
      id="Narr_MzQRM9AAXEeBQ53S57vjUg">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w"
      id="Tc_hXyz-MrP-USbBjkwz2QL1g_1_0">American Depositary Shares, each representing 6 Ordinary Shares, par value &#xa3;0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w"
      id="Tc__XZIvw8OgEWISOtuRjcZTg_1_2">ADAP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w"
      id="Narr_o8VDxFgVE0-Fg2VtHLtLag">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_9_6_2025_To_9_6_2025_BmYjMysFK0GPGoaev-xM1w"
      id="Narr_rHdD2-5i_0a4243_I4_Qfw">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
